UNIVERSITE CLERMONT AUVERGNE;VALBIOTIS;CNRS;UNIVERSITE DE LA ROCHELLE
发明人:
申请号：
IL26827119
公开号：
IL268271D0
申请日:
2019.07.25
申请国别(地区):
IL
年份:
2019
代理人:
摘要：
The invention relates to an active pharmaceutical ingredient consisting exclusively of the combination of (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and of methyl (2S,3E,4S)-4-{2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-2H -pyran-5-carboxylate for use as a drug or veterinary product, particularly in the prevention and/or treatment of pathological disorders of carbohydrate and/or lipid metabolism.
